News & Updates

The novel oral, non-peptide glucagon-like peptide-1 receptor agonist (GLP-1 RA) orforglipron gains the upper hand over the current leading oral GLP-1 RA, semaglutide, in individuals with type 2 diabetes (T2D) inadequately controlled on metformin in the phase III ACHIEVE-3 study.

Combination treatment with phentermine-topiramate extended release (ER) and a digitally enhanced lifestyle intervention (DELI) results in a significant and sustained weight reduction, as well as a decrease in cardiovascular disease (CVD) risk, in adults with obesity, reports a study.

In an observational study of two community-based cohorts in Hong Kong, 6.7 percent of individuals with BMI ≥25 kg/m² were reclassified as nonobese after applying the Lancet Commission’s definition of obesity. Individuals with clinical obesity had the highest risk of adverse cardiovascular-kidney-metabolic (CKM) outcomes, while those reclassified as nonobese had an intermediate risk. 

Albuminuria is an important and independent predictor of hip fractures and major osteoporotic fractures (MOF) in patients with type 2 diabetes (T2D), and the presence of additional metabolic syndrome (MetS)–related traits compounds this fracture risk, particularly in nonobese patients, a population-based retrospective cohort study in Hong Kong has shown.

A smart speaker appears to have gone beyond its initial capabilities, improving mental health and diabetes-related outcomes in older adults with type 2 diabetes (T2D) in the Brazilian IVAM-ED* trial.